A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications

RM Reilly, DA Scollard, J Wang, H Mondal… - Journal of Nuclear …, 2004 - Soc Nuclear Med
Our goal was to design and manufacture a kit under good manufacturing practices (GMP) for
the preparation of 111In-DTPA-hEGF Injection, a novel targeted radiotherapeutic agent for …

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron–emitting …

RM Reilly, P Chen, J Wang, D Scollard… - Journal of Nuclear …, 2006 - Soc Nuclear Med
Our objective was to evaluate the pharmacokinetics, normal tissue distribution, radiation
dosimetry, and toxicology of human epidermal growth factor (hEGF) labeled with 111In …

[HTML][HTML] Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of 111In-DTPA-human epidermal growth factor in patients with …

KA Vallis, RM Reilly, D Scollard, P Merante… - American journal of …, 2014 - ncbi.nlm.nih.gov
The safety, pharmacokinetics, biodistribution and radiation dosimetry of 111 In-DTPA-hEGF,
an Auger electron-emitting radiopharmaceutical, were evaluated in a first-in-human trial …

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive …

P Chen, R Cameron, J Wang, KA Vallis… - Journal of nuclear …, 2003 - Soc Nuclear Med
The epidermal growth factor receptor (EGFR) is an attractive target for the design of
radiotherapeutic agents for breast cancer because it is present on almost all estrogen …

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron–emitting radiopharmaceutical 111In-DTPA …

KE Bailey, DL Costantini, Z Cai… - Journal of Nuclear …, 2007 - Soc Nuclear Med
111In-DTPA–human epidermal growth factor (111In-DTPA-hEGF [DTPA is
diethylenetriaminepentaacetic acid]) is an Auger electron–emitting radiopharmaceutical that …

Amplified delivery of indium-111 to EGFR-positive human breast cancer cells

J Wang, P Chen, ZF Su, K Vallis, J Sandhu… - Nuclear medicine and …, 2001 - Elsevier
A method is described to amplify the delivery of 111In to human breast cancer cells utilizing
a novel human serum albumin-human EGF (HSA-hEGF) bioconjugate substituted …

[PDF][PDF] A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer

RM Reilly, R Kiarash, J Sandhu, YW Lee… - Journal of Nuclear …, 2000 - Soc Nuclear Med
Division ofNuclear Medicine and Departments ofPathology and Radiation Oncology,
Toronto General HospitaL/Princess Margaret Hospital, University Health Network, Toronto; …

[PDF][PDF] 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR

RM Reilly, R Kiarash, RG Cameron… - Journal of Nuclear …, 2000 - Soc Nuclear Med
Overexpression of the epidermal growth factor (EGF) receptor (EGFR) at levels up to 100
times higher than that observed on normal epithelial cells has been observed in 30% — …

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In] DTPA-hEGF

M Hu, D Scollard, C Chan, P Chen, K Vallis… - Nuclear medicine and …, 2007 - Elsevier
INTRODUCTION: Our objective was to evaluate the effect of epidermal growth factor
receptor (s)(EGFR) density on the importation and nuclear localization of 111In-labeled …

A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells …

C Panosa, H Fonge, M Ferrer-Batallé… - Nuclear Medicine and …, 2015 - Elsevier
Introduction EGFt is a truncated form of human epidermal growth factor (hEGF) that is non-
biologically active but retains binding and internalization into EGFR-positive cells. Our aim …